JURY AWARDS $3.6 MILLION IN FIRST BARD IVC TRIAL

In the first bellwether trial of the Bard IVC Filter litigation, a federal jury ruled against the manufacturer C. R. Bard. On March 30, 2018, jurors in Phoenix ordered Bard to pay $1.6 million in compensatory damages to Plaintiff Sherr-Una Booker, who was harmed by an inferior vena cava (IVC) filter made by C. R. Bard. Howard L. Nations of The Nations Law Firm was a member of the trial team and represented Ms. Booker in Court. In the trial that lasted more than 2 weeks, the jury decided that Bard is 80% liable for Ms. Booker’s injuries. Bard was also ordered to pay an additional $2 million in punitive damages, taking the jury only 16 minutes to reach their decision.

This is one of several thousand lawsuits filed against the New Jersey-based Bard Company, the first IVC trial against Bard, and only the second trial against an IVC filter manufacturer, the first being a case against Cook Medical last November in Florida.

In Ms. Booker’s case, the IVC filter tilted, perforated her vena cava, broke apart, and pieces of the metal device then traveled to her spine and heart. As a result, she underwent open-heart surgery in 2014 to repair the damage and attempt to remove the broken filter parts. They were unable to remove a piece of the filter near her heart and it remains there today, leaving Ms. Booker with the ever constant fear that at any moment the piece of metal could move again and cause an imminent risk of death.

WHAT IS AN IVC FILTER?

IVC filters (inferior vena cava filters) are implanted in the vena cava, the largest vein in the body, which carries de-oxygenated blood to the right atrium of the heart and to the lungs. The implants are used in patients for various conditions, namely deep vein thrombosis in the legs. These devices are intended to prevent blood clots from breaking off and migrating to the organs such as the heart, brain and lungs, where blood clots settle and can become life-threatening.

If you or someone you know may have developed complications after IVC implantation, please contact our offices at (800) 269-3050 or fill out this form for a free case evaluation.

Risperdal Case “Short-Form” Plaintiff’s Fact Sheet (PFS)

By Buck Daniel

Recent developments in the Risperdal litigation include court-approved “short-form” plaintiff’s fact sheets (PFS) and a renewed push for the first bellwether trial in California. If we have filed your case, then attorney Buck Daniel has been trying to reach out to you in order to discuss the upcoming process and we have sent out a short-form PFS for you to complete and return. If you have not spoken with our office, or if you have not yet received a short-form PFS, please reach out to us immediately. It is the hope of plaintiff’s leadership that the first Risperdal case in California will be brought to trial by summer 2016, and as developments occur, we will keep you up to date.

Judge Sets Trial Dates in Actos MDL

Posted by Buck Daniel

November 7, 2012 – A scheduling order issued by Judge Rebecca Doherty has set the first Actos lawsuit trial to begin on November 3, 2014 with a second trial scheduled for July 8, 2015. The judge also stated in the scheduling order that the attorneys for plaintiffs and defendants must select these potential trial cases by June 3, 2013 so that a definitive order and roster of parties can be finalized. The parties will have until September 30, 2013 to complete core discovery in these cases.

Judge Doherty stated in the scheduling order that even though these court cases are more than two years from now, the large scope of the litigation, the number of plaintiffs who have already filed Actos bladder cancer claims and the number of additional plaintiffs who could join the litigation that these deadlines need to be met in order for the case to avoid potentially long delays.